免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Gene Therapy
The Gene Editing Technology Innovation Platform
Hematopoietic Stem Cell Platform

Gene Editing Technology Innovation Platform

Gene Editing Technology Innovation Platform

The Gene Editing Technology Innovation Platform (CRISTARS®) is dedicated to developing international leading gene editing tools, obtaining core technologies with independent intellectual property rights, and paving the important foundation for gene editing technology translation. The platform is based on the combination of different single-stranded DNA deaminase structural domains and Cas9 nickase to develop a new generation of DNA base editing tools for broader and more accurate gene editing. The platform has successfully created the world-leading dual base editor and the ultra-high activity cytidine single-base editor (hyper CBE, HyCBE), which can efficiently convert two bases, improve editing activity and broaden the target range. The research results have been published in high-impact peer-review journals such as Nature Biotechnology, Nature Cell Biology, and Cell Research.

World's first successful application of CRISPR/Cas9 for mammalian gene editing

Gene editing is a technology to modify genes with precise modifications, which can be achieved with high efficiency and specificity for specific genomic DNA (or RNA), just as freely and accurately as editing text. In August 2013, a team of Bioraylab scientists published in the prestigious international journal Nature Biotechnology (IF≈43.11) the description of The CRISPR/Cas9 system was successfully used to edit genes in mice and rats. In the years since, Bioraylab scientists have continued to improve the gene editing system, applying it to a variety of applications including gene therapy, cell therapy and humanized animals.

The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产三级午夜理伦三级 | 久久99精品久久久久久无毒不卡网站查找 | 精品成人无码久久久久 | 在线播放黄色网址 | 一区二区在线视频 | 114国产精品久久免费观看 | 69精品人人槡人妻人人玩简单 | 69精品人人人人人人人人人 | 国产在线不卡 | 午夜无码在线 | 国产乱伦精品一区二区三区 | 玖玖玖在线资源 | 亚洲精品乱码一品二品三品欧美 | 91在线视频| 久久偷偷做嫩草影院免费看 | 熟女高潮视频 | 精品传媒一区二区三区A片 无码人妻精品一区二区三区不卡 | 亚洲一区二区三区无码 | 午夜精品久久久久久久爽 | 无码喷水 | 国产人妻人伦精品熟女 | 性一交一乱一交A片久久四色 | 成人午夜福利视频镇东影视 | 亚洲综合欧美另类 | 红桃 网站国产精品 | 又粗又硬又爽18级A片 | 玖草在线 | 精品国产Av | 亚洲AV高清 | 三级黃色三級三級三級 | 国产精品扒开腿做爽爽爽A片唱戏 | 无码免费视频在线播放 | 东方成人av | 无码人妻丰满熟妇精品区东京直播 | 7799精品视频天天综合在线观看 | 国产无套内射普通话对白 | 无码免费一区二区三区 | 日本另类αv欧美另类aⅴ | 自慰一区 | 国产成a人亚洲精v品无码 | 亚洲视频二区 |